Yasemin Bolukbasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasemin Bolukbasi has a total of 281 co-authors. Here are the top co-authors by number of shared publications:
- Ugur Selek
Koc University, School of Medicine
16 shared publications Duygu Sezen
8 shared publications- Deniz Yalman
Ege University, Faculty of Medicine, Department of Radiation Oncology, Izmir, Turkey
6 shared publications Ugur Selek
Koc Univ, Fac Med, Dept Radiat Oncol, Davutpasa Caddesi 4, TR-34010 Istanbul, Turkey
6 shared publicationsErkan Topkan
Başkent University
5 shared publicationsDeniz Yalman
Department of Radiation Oncology, Ege University Medical School, Izmir, Turkey
4 shared publications
Latest Publications
- Open Access
Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.
Open AccessInduction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.
- Open Access
- 9 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 278
Significant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Background: Accurate identification of complete or near-complete responders after total neoadjuvant therapy (TNT) is critical for selecting candidates for non-operative management in locally advanced rectal cancer (LARC). While static inflammatory biomarkers have been widely investigated, the predictive value of dynamic changes in systemic inflammation during TNT remains unclear. This study evaluated whether changes in the Pan-Immune Inflammation Value (PIV) correlate with magnetic resonance imaging tumor regression grade (mrTRG) and regrowth risk. Methods: Seventy-three patients with LARC treated with TNT between 2018 and 2024 were retrospectively analyzed. Patients were classified as complete/near-complete responders (C-NCRG; mrTRG1–2) or residual disease group (RDG; mrTRG3–5). The PIV was calculated as (platelet × monocyte × neutrophil)/lymphocyte at treatment initiation (first-PIV), three weeks after completion of chemotherapy (last-PIV), and at regrowth (Rg-PIV). Dynamic changes were defined as Δ-PIV (last-PIV minus first-PIV) and ΔRg-PIV (Rg-PIV minus first-PIV). Receiver operating characteristic analysis identified optimal cutoffs, and logistic regression assessed independent associations. Results: The baseline PIV did not differ between groups. Last-PIV and Δ-PIV were significantly lower in the C-NCRG compared with RDG (p = 0.006). A Δ-PIV cutoff of −36.9 discriminated responders (AUC = 0.705; sensitivity 53.7%; specificity 84.4%) and remained independently associated with MRI response in multivariate analysis. In the non-operative management cohort, ΔRg-PIV was significantly lower in patients without regrowth (p = 0.001), with a cutoff of −77.72 (AUC = 0.794; sensitivity 88.9%; specificity 66.7%). Overall survival was superior in the C-NCRG (p = 0.01). Conclusions: A dynamic reduction in the PIV during TNT is significantly associated with favorable MRI response and lower regrowth risk in LARC. PIV dynamics may serve as a noninvasive complementary biomarker to support response assessment and stratification in organ-preservation strategies.
- 9 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (5) , 278
Open AccessSignificant Correlation of Dynamic Pan-Immune Inflammation Value and Magnetic Resonance Imaging Response in Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy
Background: Accurate identification of complete or near-complete responders after total neoadjuvant therapy (TNT) is critical for selecting candidates for non-operative management in locally advanced rectal cancer (LARC). While static inflammatory biomarkers have been widely investigated, the predictive value of dynamic changes in systemic inflammation during TNT remains unclear. This study evaluated whether changes in the Pan-Immune Inflammation Value (PIV) correlate with magnetic resonance imaging tumor regression grade (mrTRG) and regrowth risk. Methods: Seventy-three patients with LARC treated with TNT between 2018 and 2024 were retrospectively analyzed. Patients were classified as complete/near-complete responders (C-NCRG; mrTRG1–2) or residual disease group (RDG; mrTRG3–5). The PIV was calculated as (platelet × monocyte × neutrophil)/lymphocyte at treatment initiation (first-PIV), three weeks after completion of chemotherapy (last-PIV), and at regrowth (Rg-PIV). Dynamic changes were defined as Δ-PIV (last-PIV minus first-PIV) and ΔRg-PIV (Rg-PIV minus first-PIV). Receiver operating characteristic analysis identified optimal cutoffs, and logistic regression assessed independent associations. Results: The baseline PIV did not differ between groups. Last-PIV and Δ-PIV were significantly lower in the C-NCRG compared with RDG (p = 0.006). A Δ-PIV cutoff of −36.9 discriminated responders (AUC = 0.705; sensitivity 53.7%; specificity 84.4%) and remained independently associated with MRI response in multivariate analysis. In the non-operative management cohort, ΔRg-PIV was significantly lower in patients without regrowth (p = 0.001), with a cutoff of −77.72 (AUC = 0.794; sensitivity 88.9%; specificity 66.7%). Overall survival was superior in the C-NCRG (p = 0.01). Conclusions: A dynamic reduction in the PIV during TNT is significantly associated with favorable MRI response and lower regrowth risk in LARC. PIV dynamics may serve as a noninvasive complementary biomarker to support response assessment and stratification in organ-preservation strategies.
- Open Access
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Lymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- 4 August 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 301-306
Open AccessLymphedema and Axillary-Lateral Thoracic Vessel Juncture Irradiation: A Clinical Dilemma
Regional nodal irradiation (RNI) is one of the main causes of breast cancer-related lymphedema (BCRL). However, studies on the relationship between the radiation dose to the axillary-lateral thoracic vessel juncture (ALTJ) region and BCRL have reported conflicting results. Based on these findings, we aimed to evaluate the clinical relevance of the dose to the ALTJ region in our patient cohort. Patients diagnosed with breast cancer and who were treated at Koç University Hospital between 2016 and 2022 and received RNI were included. BCRL was defined as a difference in arm circumference between the ipsilateral and contralateral limb >2.5 cm at any single encounter or ≥2 cm on ≥2 visits. ALTJ was retrospectively contoured, and doses were recorded as equivalent dose (α/β = 3). Of the 129 patients (median age 49 years) who met the inclusion criteria, 12 (9.3%) had lymphedema. Two-thirds of the patients (66.7%) were stage II, and one-third (33.3%) were stage III. The median follow-up was 22 months. The median (range) ALTJ Dmean dose was 18.11 (1.87-50) Gy, the median ALTJ Dmax was 44.53 (12.8-71.1) Gy, and the median ALTJ V35 was 38% (1-100%). No significant association was determined between ALTJ parameters and BCRL. There is insufficient data to define ALTJ as an OAR for decreasing BCRL risk. It is not appropriate to define dose and target based on ALTJ. Prospective studies with larger patient populations are needed to clarify the relationship between ALTJ and lymphedema.
- Open Access
- 21 January 2025
- Published by Elsevier in The Breast
- Vol. 80, 103881
The 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy
- 21 January 2025
- Published by Elsevier in The Breast
- Vol. 80, 103881
Open AccessThe 2024 Assisi think tank on breast cancer: Focus on the use of a tumour bed boost after breast conserving therapy
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (3) , 251-256
FAST- Forward Radiotherapy in Breast Cancer Patients from a Turkish Cohort: A Study on Acute Skin Toxicity
- 1 January 2024
- Published by LookUs Bilisim A.S. in Turkish Journal of Oncology
- Vol. 39 (3) , 251-256
FAST- Forward Radiotherapy in Breast Cancer Patients from a Turkish Cohort: A Study on Acute Skin Toxicity
- Open Access
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35280
Investigating the levels of depression, anxiety, sexual disorders, and other influencing factors in breast cancer patients: Turkish radiation oncology integrative group study (TROD 12-05)
The fear of death associated with cancer and the side effects of its treatments can have a detrimental psychological impact on breast cancer patients. Early detection and support services play a crucial role in alleviating the expected symptoms of depression, anxiety, and sexual dysfunction. The objective of our study is to assess the levels of depression, anxiety, and sexual dysfunction in breast cancer patients, as well as identify the factors that influence these conditions. The study involved 329 voluntarily participating breast cancer patients who had undergone surgery and were in the follow-up stage. Data were collected from 8 different centers after obtaining ethical approval. The assessment utilized tools such as the Sociodemographic Information Form, Beck Depression and Anxiety Scale, and Arizona Sexual Experiences Scale. Data analysis was performed using SPSS 20. The study included 329 breast cancer patients in the follow-up stage post-surgery. Their average age was 52.7 years (range: 27–83). Results indicated that 33.1% experienced moderate to severe depression, 18.2% reported severe anxiety, and 82.7% scored above 11 on the sexual scale. Factors linked to higher scores were mastectomy, surgical dissatisfaction, insufficient information on sexual side effects, and comorbidities like smoking and diabetes. The study emphasizes the importance of closely monitoring anxiety, depression levels, and sexual side effects in breast cancer treatment. It underscores the need to focus not only on reducing mortality rates but also on supporting patients’ psychological and sexual well-being, ultimately improving their overall quality of life.
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e35280
Open AccessInvestigating the levels of depression, anxiety, sexual disorders, and other influencing factors in breast cancer patients: Turkish radiation oncology integrative group study (TROD 12-05)
The fear of death associated with cancer and the side effects of its treatments can have a detrimental psychological impact on breast cancer patients. Early detection and support services play a crucial role in alleviating the expected symptoms of depression, anxiety, and sexual dysfunction. The objective of our study is to assess the levels of depression, anxiety, and sexual dysfunction in breast cancer patients, as well as identify the factors that influence these conditions. The study involved 329 voluntarily participating breast cancer patients who had undergone surgery and were in the follow-up stage. Data were collected from 8 different centers after obtaining ethical approval. The assessment utilized tools such as the Sociodemographic Information Form, Beck Depression and Anxiety Scale, and Arizona Sexual Experiences Scale. Data analysis was performed using SPSS 20. The study included 329 breast cancer patients in the follow-up stage post-surgery. Their average age was 52.7 years (range: 27–83). Results indicated that 33.1% experienced moderate to severe depression, 18.2% reported severe anxiety, and 82.7% scored above 11 on the sexual scale. Factors linked to higher scores were mastectomy, surgical dissatisfaction, insufficient information on sexual side effects, and comorbidities like smoking and diabetes. The study emphasizes the importance of closely monitoring anxiety, depression levels, and sexual side effects in breast cancer treatment. It underscores the need to focus not only on reducing mortality rates but also on supporting patients’ psychological and sexual well-being, ultimately improving their overall quality of life.
- 1 June 2023
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 39 (2) , 95-102
Optimized Hybrid Arc for Improved Sparing of Organs at Risk: Balanced Combination of IMRT and VMAT in Prostate Cancer
- 1 June 2023
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 39 (2) , 95-102
Optimized Hybrid Arc for Improved Sparing of Organs at Risk: Balanced Combination of IMRT and VMAT in Prostate Cancer
- Open Access
- 16 September 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (5) , 100988
In Regard to Shee et al
- 16 September 2022
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 7 (5) , 100988
Open AccessIn Regard to Shee et al
- Open Access
- 24 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7051
Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia
Glioblastoma is the most malignant primary brain tumor, and a cornerstone in its treatment is radiotherapy. However, tumor cells surviving after irradiation indicates treatment failure; therefore, better understanding of the mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated clinically relevant irradiation-exposed models by applying fractionated radiotherapy over a long time and selecting irradiation-survivor (IR-Surv) glioblastoma cells. We examined the transcriptomic alterations, cell cycle and growth rate changes and responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Concomitantly, IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, and MGMT, and had better DNA repair capacity. IR-Surv cells displayed downregulation of hypoxic signature and lower induction of hypoxia target genes, compared to naïve glioblastoma cells. Moreover, Chk1 inhibition alone or in combination with irradiation significantly reduced cell viability in both naïve and IR-Surv cells. However, IR-Surv cells’ response to Chk1 inhibition markedly decreased under hypoxic conditions. Taken together, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions.
- 24 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7051
Open AccessChronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia
Glioblastoma is the most malignant primary brain tumor, and a cornerstone in its treatment is radiotherapy. However, tumor cells surviving after irradiation indicates treatment failure; therefore, better understanding of the mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated clinically relevant irradiation-exposed models by applying fractionated radiotherapy over a long time and selecting irradiation-survivor (IR-Surv) glioblastoma cells. We examined the transcriptomic alterations, cell cycle and growth rate changes and responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Concomitantly, IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, and MGMT, and had better DNA repair capacity. IR-Surv cells displayed downregulation of hypoxic signature and lower induction of hypoxia target genes, compared to naïve glioblastoma cells. Moreover, Chk1 inhibition alone or in combination with irradiation significantly reduced cell viability in both naïve and IR-Surv cells. However, IR-Surv cells’ response to Chk1 inhibition markedly decreased under hypoxic conditions. Taken together, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions.
- Open Access
Chronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition
Glioblastoma is the most common type of primary brain tumor with an aggressive clinical course, and one of the cornerstones in its treatment regimen is radiotherapy. However, tumor cells surviving after radiation is an indicator of treatment failure; therefore, better understanding of the molecular mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated multiple clinically relevant irradiation exposed models, where we applied fractionated radiotherapy over a long period of time and selected irradiation-survivor (IR-Surv) glioblastoma cell populations. In these cells, we examined the transcriptomic alterations, cell cycle and growth rate changes as well as responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Transcriptomic analysis revealed that IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, MGMT, and had better DNA repair capacity as an adaptive mechanism. Separately, we report IR-Surv cells to display downregulation of hypoxic signature and the lower induction of hypoxia target genes and not exhibiting the same level of hypoxia-induced changes with naïve glioblastoma cells, as gauged by exposing cells to different hypoxia conditions. We also showed that Chk1 inhibition alone or in combination with irradiation significantly reduces cell viability in both naïve and IR-Surv cells. However, IR-Surv cells were markedly less sensitive to Chk1 inhibition under hypoxic conditions. In conclusion, consistent with previous reports, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions. Thus, our findings with clinically relevant radiation survivor models will have future translational implications and benefit the optimization of combination therapies for glioblastoma patients.
Open AccessChronically radiation-exposed survivor glioblastoma cells display poor response to Chk1 inhibition
Glioblastoma is the most common type of primary brain tumor with an aggressive clinical course, and one of the cornerstones in its treatment regimen is radiotherapy. However, tumor cells surviving after radiation is an indicator of treatment failure; therefore, better understanding of the molecular mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated multiple clinically relevant irradiation exposed models, where we applied fractionated radiotherapy over a long period of time and selected irradiation-survivor (IR-Surv) glioblastoma cell populations. In these cells, we examined the transcriptomic alterations, cell cycle and growth rate changes as well as responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Transcriptomic analysis revealed that IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, MGMT, and had better DNA repair capacity as an adaptive mechanism. Separately, we report IR-Surv cells to display downregulation of hypoxic signature and the lower induction of hypoxia target genes and not exhibiting the same level of hypoxia-induced changes with naïve glioblastoma cells, as gauged by exposing cells to different hypoxia conditions. We also showed that Chk1 inhibition alone or in combination with irradiation significantly reduces cell viability in both naïve and IR-Surv cells. However, IR-Surv cells were markedly less sensitive to Chk1 inhibition under hypoxic conditions. In conclusion, consistent with previous reports, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions. Thus, our findings with clinically relevant radiation survivor models will have future translational implications and benefit the optimization of combination therapies for glioblastoma patients.